Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-man study of Twincer dry powder influenza vaccine
NL-OMON44937Withdrawn
- Sponsor
- University of Groningen
- Start
- Feb 2016
- Countries
- 1
01
Overview
Open-label trial in influenza (4 arms), sponsored by University of Groningen. Primary endpoints: Acute adverse events within 6 hours, FEV reduction greater than 20% and 8 more. Planned start Feb 2016; status: withdrawn.
02
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON44937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44937.